Compare AMSS & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMSS | SER |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6M | 30.6M |
| IPO Year | N/A | N/A |
| Metric | AMSS | SER |
|---|---|---|
| Price | $1.21 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 430.4K | 34.0K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $1.22 |
| 52 Week High | $2.44 | $7.92 |
| Indicator | AMSS | SER |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 53.31 |
| Support Level | $0.83 | $1.74 |
| Resistance Level | $1.30 | $2.26 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 47.76 | 45.57 |
Amass Brands Inc is building a diversified premium beverage platform at the intersection of craft, wellness, and functionality. The company operates in the beverage industry, offering a portfolio that includes spirits, wine, and non-alcoholic products. The company distributes its brands in the United States through wholesale, on-premise, and direct-to-consumer channels. The company has two segments: Wine and Spirits. The majority of the company's revenue is derived from the Wine segment, which offers a portfolio of premium imported and domestic wine brands. Geographically, it operates predominantly in the USA.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.